MapLight Therapeutics (MPLT) News
What's actually happening: chronological and provenance-stamped. News is context, not a signal.
The percentage on each card is MPLT's move today, from the quote feed. It is the same figure on every headline, not the move on that headline's own date.

Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in 2028…

SAN FRANCISCO and BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference: Event: 202…

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) insider Erin Pennock Foff sold 15,355 shares of the company's stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $8…

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) insider Anatol Kreitzer sold 12,248 shares of the stock in a transaction dated Thursday, October 15th. The stock was sold at an average price of $7.84, for a t…

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) CFO Jonathan Gillis sold 10,167 shares of Maplight Therapeutics stock in a transaction dated Thursday, October 15th. The shares were sold at an average price o…

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) insider James Lillie sold 11,513 shares of Maplight Therapeutics stock in a transaction dated Thursday, October 15th. The shares were sold at an average price …

The heavy selling pressure might have exhausted for MapLight Therapeutics, Inc. (MPLT) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in…

Maplight Therapeutics, Inc. (NASDAQ: MPLT - Get Free Report) has received a consensus rating of "Moderate Buy" from the eighteen analysts that are currently covering the firm, Marketbeat reports. One analyst has rated th…

MapLight Therapeutics, Inc. (MPLT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising e…

Award honors foundational discoveries in optogenetics and circuit mapping These discoveries laid the foundation for a new era in neuroscience and helped inspire MapLight's circuit-based approach to drug discovery SAN FRA…

SAN FRANCISCO and BOSTON, Sept. 09, 2026 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc. (Nasdaq: MPLT) today announced that members of its management team will participate in the following investor conference:…

BlackRock Inc. acquired a new position in shares of Maplight Therapeutics, Inc. (NASDAQ: MPLT) in a recent quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The instituti…
Kept in their own lane. A press release is the company talking, not reporting.
No upcoming events in the feeds.

